Comparing neurocognitive impairment in schizophrenia and bipolar I disorder using the Screen for Cognitive Impairment in Psychiatry Scale

The purpose of this study was to compare the psychometric properties of the Screen for Cognitive Impairment in Psychiatry (SCIP) when applied to patients diagnosed with schizophrenia (n = 126) or bipolar I disorder (n = 76), and also to compare the cognitive impairment in both samples of patients and a control group (n = 83) using the SCIP and a complete neuropsychological battery. The SCIP is a scale intended to quickly and easily assess cognitive impairment in patients with severe psychiatric disorders. The results showed firstly that, in terms of internal consistency, temporal stability, dimensional structure, and criterionreferenced validity, the SCIP provides reliable and valid scores at an equivalent level in both schizophrenia and bipolar I disorder samples. Secondly, it showed that differential cognitive impairment between the two patient groups occurs only in verbal memory, although the effectThe statistical analysis of this work was funded by Pfizer, S.L.U. Data collection in the original study source for the analysis included here was funded by Pfizer, SLU, and also received grants from Ministerio de Economía y Competitividad (PSI2012-32275), Instituto de Salud Carlos III, CIBERSAM and the Ministerio de Sanidad y Consumo: Plan Nacional de Drogas (2008/I/30) and Gobierno de Navarra (GON 55/200). Editorial support was funded by project 2009SGR0822 (J. Gómez-Benito y G. Guilera) and 2009SGR1022 (E. Vieta y A. Martínez-Arán) from Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya. Grammatical review was carried out by Sharon Grevet and was funded by Pfizer, SLU. Javier Rejas is employ of Pfizer, SLU. All other authors declare that they have no conflict of interest as a consequence of this work